GSK plc stock (GB0009252882): Shares firm up ahead of valuation focus on London market

GSK plc shares gained ground on the London Stock Exchange, with investors watching the UK pharma group’s current valuation metrics as the week ends. The move comes as the FTSE 100 constituent continues to trade near the upper half of its 52-week range.

GSK plc shares were firmer on the London Stock Exchange on 06/05/2026, with the stock quoted around 1,903 pence during the session, up about 2.7% on the day according to data from AJ Bell as of 06/05/2026AJ Bell as of 06/05/2026.

The UK-based pharmaceutical group, a member of the FTSE 100 index, has been under close watch from investors as it trades in the upper half of its 52-week range, with a one-year performance of roughly 25.7% based on figures reported by Investing.com as of early June 2026Investing.com as of 06/04/2026.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: London, United Kingdom
• Core markets: Europe, United States, emerging markets
• Key revenue drivers: Specialty medicines, vaccines, and general medicines
• Home exchange/listing venue: London Stock Exchange (GSK)
• Trading currency: GBP

GSK plc: core business model

GSK focuses on researching, developing, and commercializing prescription medicines and vaccines, with revenue mainly generated from specialty therapies, respiratory and HIV treatments, and a broad vaccines portfolio.

Valuation metrics and multiples for GSK plc

With GSK plc’s share price around 1,903 pence on the London Stock Exchange on 06/05/2026, investors are paying close attention to how this level compares with the company’s historical trading range and recent fundamental performance, particularly after a one-year gain of about 25.7% reported by Investing.com as of early June 2026Investing.com as of 06/04/2026.

External valuation tools also highlight how current pricing relates to modeled intrinsic value, with GuruFocus noting on 06/04/2026 that GSK’s US-listed shares around USD 51.27 were about 16.5% above its GF Value estimate of USD 43.99, implying a premium to that specific fair-value model at that dateGuruFocus as of 06/04/2026.

Conclusion

GSK plc’s share price strength on the London Stock Exchange on 06/05/2026, combined with a one-year gain of about 25.7%, keeps the UK pharma group in focus for investors assessing large-cap healthcare names.

Against this backdrop, valuation metrics such as external fair-value models and the stock’s position within its 52-week range provide a reference point for how the current market price relates to historical levels and modeled intrinsic value without implying any view on future performance.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.